Who was studied, and how
One number in the abstract
Where each one falls
Where it lands on the map
10,251people in the Action to Control Cardiovascular Risk in Diabetes trial, from 1999
4,159of them with cardiovascular disease, in this paper
Among study participants with dyslipidemia, defined as triglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34 mg/dL, the trial randomly assignedassigned by chance
fenofibrate
placebo
May have lowered CVD−27%
randomised · one subgroupthe abstract, start to end
… levels less than 34 mg/dL (HR, 0.73; 95% CI, 0.56-0.95).
← favours treatmentfavours comparator →
could be chanceCVDfenofibrate vs placebo, in study participants with dyslipidemia, defined as triglyceride levels greater than 204 mg/dL and high-density lipoprotein cholesterol levels less than 34 mg/dL
HR 0.730.56–0.95
Other lipid agentsLipids
1 / 4